AstraZeneca reported Phase 3 success for tozorakimab (IL-33 antibody) in COPD trials Oberon and Titania, with results meeting the main goal in both studies across broader patient populations than expected. The company said the trials included former and current smokers and patients across all blood eosinophil counts and stages of lung function severity, potentially widening the eligible use base beyond current eosinophil-restricted biologics. The article emphasizes that the outcome surprised Wall Street because IL-33 blockade has produced mixed or negative results in late-stage testing for other programs. AstraZeneca has not released complete data yet, saying details will be presented at an upcoming medical meeting, which is likely to determine the shape of eventual label and competitive positioning. For the biotech market, the readout is a high-impact pipeline update in respiratory immunology and may shift expectations for how IL-33 biology translates into real-world COPD endpoints.